Skip to main content

HCC 22: Bladder, Colorectal, and Other Cancers

HCC 22, Bladder, Colorectal, and Other Cancers, is one of the 115 payment categories in the CMS-HCC V28 model. 126 ICD-10-CM codes map to it in the payment year 2027 mapping, and a documented diagnosis in the category adds a relative factor of 0.363 to the risk score of a community, non-dual, aged beneficiary (0.366 disabled, 0.314 institutional). It is overridden when a more severe category in its hierarchy is present (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21) and it in turn overrides HCC 23. In its hierarchy, HCC 21 overrides it when both are coded, at a community aged factor of 0.671 (+0.308), and it overrides HCC 23 (0.186, -0.177), so a record coding both is paid this category's factor alone.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ICD-10-CM to HCC mapping: PY2027 initial ICD-10-CM mappings (dates of service 2026) (payment year 2027); CMS-HCC V28 model software: CMS-HCC V28 software V2826.115.T2 (PY2027 initial) (payment year 2027). Next CMS release: PY2028 advance notice (February 2027) and the PY2027 midyear final mapping (spring 2027).

Mapped ICD-10-CM codes
126
Factor, community non-dual aged
0.363
Factor, institutional
0.314
Hierarchy
Overridden by HCC 17, HCC 18, HCC 19, HCC 20, HCC 21
Disease group
Neoplasm

Relative factors by segment

Each segment is a separate regression; the factor is added to the beneficiary's demographic factors and other categories, then normalized and reduced by the coding intensity adjustment before it meets the plan's base rate. A factor of 1.000 equals the expected cost of an average beneficiary.

CMS-HCC V28 relative factors for HCC 22 by model segment
SegmentModel codeRelative factor
Community, non-dual, agedCNA_HCC220.363
Community, non-dual, disabledCND_HCC220.366
Community, full-benefit dual, agedCFA_HCC220.382
Community, full-benefit dual, disabledCFD_HCC220.409
Community, partial-benefit dual, agedCPA_HCC220.410
Community, partial-benefit dual, disabledCPD_HCC220.351
Long-term institutionalINS_HCC220.314

Hierarchy

Hierarchical condition categories pay only the most severe manifestation of a disease. When HCC 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) or HCC 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid) or HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers) or HCC 20 (Lung and Other Severe Cancers) or HCC 21 (Lymphoma and Other Cancers) is also documented for the same beneficiary, HCC 22 is dropped from the score. When HCC 22 is present it drops HCC 23 (Prostate, Breast, and Other Cancers and Tumors), so documenting the less severe condition alongside it adds nothing to payment but still matters for the clinical record.

ICD-10-CM codes that map to HCC 22

126 codes map to this category in the PY2027 initial mapping, concentrated in the D3A (22), C57 (14), C91 (12), C18 (10), C67 (10), C74 (9) code families. CMS built that mapping from codes valid in FY2025 and FY2026, and descriptions are the CMS mapping descriptions. None of these codes was deleted in the October 1, 2026 update.

ICD-10-CM codes mapped to HCC 22 in the CMS PY2027 initial mapping
ICD-10-CMDescription
C18.0Malignant neoplasm of cecum
C18.1Malignant neoplasm of appendix
C18.2Malignant neoplasm of ascending colon
C18.3Malignant neoplasm of hepatic flexure
C18.4Malignant neoplasm of transverse colon
C18.5Malignant neoplasm of splenic flexure
C18.6Malignant neoplasm of descending colon
C18.7Malignant neoplasm of sigmoid colon
C18.8Malignant neoplasm of overlapping sites of colon
C18.9Malignant neoplasm of colon, unspecified
C19Malignant neoplasm of rectosigmoid junction
C20Malignant neoplasm of rectum
C21.0Malignant neoplasm of anus, unspecified
C21.1Malignant neoplasm of anal canal
C21.2Malignant neoplasm of cloacogenic zone
C21.8Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C26.0Malignant neoplasm of intestinal tract, part unspecified
C26.1Malignant neoplasm of spleen
C26.9Malignant neoplasm of ill-defined sites within the digestive system
C51.0Malignant neoplasm of labium majus
C51.1Malignant neoplasm of labium minus
C51.2Malignant neoplasm of clitoris
C51.8Malignant neoplasm of overlapping sites of vulva
C51.9Malignant neoplasm of vulva, unspecified
C52Malignant neoplasm of vagina
C53.0Malignant neoplasm of endocervix
C53.1Malignant neoplasm of exocervix
C53.8Malignant neoplasm of overlapping sites of cervix uteri
C53.9Malignant neoplasm of cervix uteri, unspecified
C56.1Malignant neoplasm of right ovary
C56.2Malignant neoplasm of left ovary
C56.3Malignant neoplasm of bilateral ovaries
C56.9Malignant neoplasm of unspecified ovary
C57.00Malignant neoplasm of unspecified fallopian tube
C57.01Malignant neoplasm of right fallopian tube
C57.02Malignant neoplasm of left fallopian tube
C57.10Malignant neoplasm of unspecified broad ligament
C57.11Malignant neoplasm of right broad ligament
C57.12Malignant neoplasm of left broad ligament
C57.20Malignant neoplasm of unspecified round ligament
C57.21Malignant neoplasm of right round ligament
C57.22Malignant neoplasm of left round ligament
C57.3Malignant neoplasm of parametrium
C57.4Malignant neoplasm of uterine adnexa, unspecified
C57.7Malignant neoplasm of other specified female genital organs
C57.8Malignant neoplasm of overlapping sites of female genital organs
C57.9Malignant neoplasm of female genital organ, unspecified
C58Malignant neoplasm of placenta
C64.1Malignant neoplasm of right kidney, except renal pelvis
C64.2Malignant neoplasm of left kidney, except renal pelvis
C64.9Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1Malignant neoplasm of right renal pelvis
C65.2Malignant neoplasm of left renal pelvis
C65.9Malignant neoplasm of unspecified renal pelvis
C66.1Malignant neoplasm of right ureter
C66.2Malignant neoplasm of left ureter
C66.9Malignant neoplasm of unspecified ureter
C67.0Malignant neoplasm of trigone of bladder
C67.1Malignant neoplasm of dome of bladder
C67.2Malignant neoplasm of lateral wall of bladder
C67.3Malignant neoplasm of anterior wall of bladder
C67.4Malignant neoplasm of posterior wall of bladder
C67.5Malignant neoplasm of bladder neck
C67.6Malignant neoplasm of ureteric orifice
C67.7Malignant neoplasm of urachus
C67.8Malignant neoplasm of overlapping sites of bladder
C67.9Malignant neoplasm of bladder, unspecified
C68.0Malignant neoplasm of urethra
C68.1Malignant neoplasm of paraurethral glands
C68.8Malignant neoplasm of overlapping sites of urinary organs
C68.9Malignant neoplasm of urinary organ, unspecified
C74.00Malignant neoplasm of cortex of unspecified adrenal gland
C74.01Malignant neoplasm of cortex of right adrenal gland
C74.02Malignant neoplasm of cortex of left adrenal gland
C74.10Malignant neoplasm of medulla of unspecified adrenal gland
C74.11Malignant neoplasm of medulla of right adrenal gland
C74.12Malignant neoplasm of medulla of left adrenal gland
C74.90Malignant neoplasm of unspecified part of unspecified adrenal gland
C74.91Malignant neoplasm of unspecified part of right adrenal gland
C74.92Malignant neoplasm of unspecified part of left adrenal gland
C91.10Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.11Chronic lymphocytic leukemia of B-cell type in remission
C91.12Chronic lymphocytic leukemia of B-cell type in relapse
C91.40Hairy cell leukemia not having achieved remission
C91.41Hairy cell leukemia, in remission
C91.42Hairy cell leukemia, in relapse
C91.90Lymphoid leukemia, unspecified not having achieved remission
C91.91Lymphoid leukemia, unspecified, in remission
C91.92Lymphoid leukemia, unspecified, in relapse
C91.Z0Other lymphoid leukemia not having achieved remission
C91.Z1Other lymphoid leukemia, in remission
C91.Z2Other lymphoid leukemia, in relapse
C92.10Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
C92.11Chronic myeloid leukemia, BCR/ABL-positive, in remission
C92.12Chronic myeloid leukemia, BCR/ABL-positive, in relapse
C92.40Acute promyelocytic leukemia, not having achieved remission
C92.41Acute promyelocytic leukemia, in remission
C92.42Acute promyelocytic leukemia, in relapse
C95.10Chronic leukemia of unspecified cell type not having achieved remission
C95.11Chronic leukemia of unspecified cell type, in remission
C95.12Chronic leukemia of unspecified cell type, in relapse
C95.90Leukemia, unspecified not having achieved remission
C95.91Leukemia, unspecified, in remission
C95.92Leukemia, unspecified, in relapse
D3A.00Benign carcinoid tumor of unspecified site
D3A.010Benign carcinoid tumor of the duodenum
D3A.011Benign carcinoid tumor of the jejunum
D3A.012Benign carcinoid tumor of the ileum
D3A.019Benign carcinoid tumor of the small intestine, unspecified portion
D3A.020Benign carcinoid tumor of the appendix
D3A.021Benign carcinoid tumor of the cecum
D3A.022Benign carcinoid tumor of the ascending colon
D3A.023Benign carcinoid tumor of the transverse colon
D3A.024Benign carcinoid tumor of the descending colon
D3A.025Benign carcinoid tumor of the sigmoid colon
D3A.026Benign carcinoid tumor of the rectum
D3A.029Benign carcinoid tumor of the large intestine, unspecified portion
D3A.090Benign carcinoid tumor of the bronchus and lung
D3A.091Benign carcinoid tumor of the thymus
D3A.092Benign carcinoid tumor of the stomach
D3A.093Benign carcinoid tumor of the kidney
D3A.094Benign carcinoid tumor of the foregut, unspecified
D3A.095Benign carcinoid tumor of the midgut, unspecified
D3A.096Benign carcinoid tumor of the hindgut, unspecified
D3A.098Benign carcinoid tumors of other sites
D3A.8Other benign neuroendocrine tumors

What changed from V24

The payment year 2025 mapping carries both models for the same codes. Of the 126 codes it maps to V28 HCC 22, 22 had no V24 payment category (new to payment under V28); the largest source is V24 HCC 11 (Colorectal, Bladder, and Other Cancers) with 55 codes. The V28 community, non-dual, aged factor is 0.363 against 0.307 for V24 HCC 11.

V24 categories that the HCC 22 codes belonged to (PY2025 mapping)
V24 HCCV24 categoryCodes now in HCC 22V24 codes with no V28 HCCV24 factor (CNA)
11Colorectal, Bladder, and Other Cancers550 of 1330.307
10Lymphoma and Other Cancers430 of 5950.675
8Metastatic Cancer and Acute Leukemia30 of 822.659
9Lung and Other Severe Cancers30 of 1101.024

V24 and V28 number their categories independently, so the same diagnosis usually carries a different HCC number in each model. The V24 to V28 crosswalk report lists every category pair, and the glossary explains the 2020 CMS-HCC V24 model and the V28 model that replaced it.

Inpatient groups where these diagnoses land

Appendix B of the v44 MS-DRG Definitions Manual places the codes in this category in the logic of 54 MS-DRGs. The groups with the most shared codes are below; a hospital stay coded with one of these diagnoses groups there when it is the principal diagnosis, or when the DRG's logic uses it as a qualifying secondary diagnosis.

MS-DRGs whose logic lists the most HCC 22 codes
MS-DRGTitleShared codes
DRG 731Uterine and Adnexa Procedures for Malignancy with MCC29
DRG 732Uterine and Adnexa Procedures for Malignancy with CC29
DRG 733Uterine and Adnexa Procedures for Malignancy without CC/MCC29
DRG 754Malignancy, Female Reproductive System with MCC29
DRG 755Malignancy, Female Reproductive System with CC29
DRG 756Malignancy, Female Reproductive System without CC/MCC29
DRG 820Lymphoma and Leukemia with Major O.R. Procedures with MCC25
DRG 821Lymphoma and Leukemia with Major O.R. Procedures with CC25
DRG 822Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC25
DRG 656Kidney and Ureter Procedures for Neoplasm with MCC24

Local coverage policies that list these diagnoses

Medicare Administrative Contractors name covered ICD-10-CM codes in the billing and coding articles attached to their LCDs. These policies share the most codes with HCC 22 in the current Medicare Coverage Database export (one policy per topic; overlap counts after each). For the services these policies govern, the same diagnoses are covered indications, so the documentation that supports the category also supports the claim for the service.

Where these codes sat in the V22 model

The V28 recalibration renumbered and regrouped categories; this table shows which legacy V22 categories the same ICD-10 codes belonged to, which is the quickest way to reconcile a V22-era HCC gap list with the current model.

V22 categories that the HCC 22 codes mapped to
V22 HCCCodes
1155
1043
93
83

Part D: the RxHCC categories of these codes

The same diagnoses feed the RxHCC model, which adjusts Medicare Part D payments. Of the 126 codes in HCC 22, 94 also map to a prescription drug category and 32 carry none; the categories are below, and the RxHCC hub has their 2027 MA-PD, PDP and PACE factors.

RxHCC V08 categories that the HCC 22 codes map to
RxHCCCategoryCodes
RxHCC 22Prostate, Breast, Bladder, and Other Cancers and Tumors64
RxHCC 19Leukemias and Other Hematologic Cancers15
RxHCC 20Lung, Kidney, and Other Cancers; Secondary Cancer of Lymph Nodes and Other Sites6
RxHCC 21Lymphomas and Other Hematologic Cancers6
RxHCC 15Chronic Myeloid Leukemia3

Capturing and defending the category

A category counts for a payment year when a mapped diagnosis is documented at least once during the data collection year by an acceptable provider type at a face-to-face or audio-video encounter, and when the note shows the condition was monitored, evaluated, assessed or treated. Chronic conditions do not carry forward: a category that is not re-documented in the year drops out of the score, which is why annual wellness visits and problem-list reconciliation are where most recapture happens. Risk adjustment data validation audits sample enrollees and ask for the medical record behind each submitted category; an unsupported category is removed and, under the extrapolation rules, the error rate is applied across the contract. The QuickIntell risk adjustment product surfaces suspected and unsupported categories from the chart, and the HCC hub lists every V28 category with its factor and code count.

For teams evaluating QuickIntell software

Evaluate risk adjustment review software

For teams reviewing documentation across a cohort, explore source evidence, proposed findings, reviewer decisions and audit handoffs. Confirm the program, payment year and model scope during evaluation. A category lookup is not a patient-specific coding or payment determination.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

Which ICD-10 codes map to HCC 22?

126 ICD-10-CM codes map to HCC 22 in the CMS PY2027 initial mapping, for example C18.0 Malignant neoplasm of cecum; C18.1 Malignant neoplasm of appendix; C18.2 Malignant neoplasm of ascending colon; C18.3 Malignant neoplasm of hepatic flexure. The full list is on this page; a code counts only when it is documented at a face-to-face or video encounter in the data collection year and supported by the record.

How much does HCC 22 add to a risk score?

The V28 relative factor for HCC 22 is 0.363 for a community, non-dual, aged beneficiary, 0.382 for full-benefit dual aged, 0.366 for non-dual disabled and 0.314 for long-term institutional members. A factor of 1.000 equals the expected annual cost of an average beneficiary, so the category's share of the payment follows the plan's base rate for that segment.

Does HCC 22 count together with related categories?

No. Within a hierarchy only the most severe category is paid. HCC 22 is dropped when HCC 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) or HCC 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid) or HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers) or HCC 20 (Lung and Other Severe Cancers) or HCC 21 (Lymphoma and Other Cancers) is also present, and it drops HCC 23 when it is present.

What has to be documented for HCC 22 to be valid?

One of the 126 mapped codes (such as C18.0) must be recorded by an acceptable provider type during a face-to-face or audio-video encounter in the service year, with the note showing that the condition (Bladder, Colorectal, and Other Cancers) was monitored, evaluated, assessed or treated. Risk adjustment data validation audits recover payment for categories the record does not support, so the code on the claim and the assessment in the note must match.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

Relative factors and mappings are reproduced from the CMS risk adjustment model files as an operational reference. Payment depends on the plan's base rate, normalization, the coding intensity adjustment and the enrollee's segment. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.